NascaCell Technologies AG
Eurogentec and NascaCell Technologies AG sign marketing agreement
NascaCell Technologies AG / Agreement Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- Liège and Munich, July 31, 2007 – NascaCell Technologies AG, a Munich-based German biotechnology company, and Eurogentec, a Belgium corporation providing reliable and innovative services and products for the Life-Science community, based in the Liège Science Park, have signed a contract under which Eurogentec will market NascaCell’s Aptamer services worldwide. NascaCell generates Aptamers as tools for early drug development serving pharmaceutical companies world wide. Aptamers are oligonucleotides which adopt well-defined 3-dimensional structures and are highly selective ligands. They can be selected within a short time from enormously complex libraries. The rapid access, easy generation by in vitro or chemical synthesis and the binding characteristics of Aptamers make them attractive tools for early drug discovery and target validation. Aptamers are typically used as inhibitors or modulators of protein function. Unlike protein-based technologies, Aptamers can be directed against intracellular targets and are also applicable in culture supernatants. More recently, NascaCell could also demonstrate the utility of Aptamers against membrane-bound targets. 'Eurogentec is an established leader serving the life science industry. In particular their expertise as custom-tailored solution provider attracted us to Eurogentec and we believe that our Aptamer service is well complemented by their other lines of products and services. Based on the existing technological synergies and the excellent interaction with our partners at Eurogentec, we look forward to a very productive collaboration,' said Dr. Ernst Boehnlein, CEO of NascaCell. 'NascaCell is the only company offering customized Aptamers for target validation and drug discovery. So, it is a great opportunity for Eurogentec to add this service for our clients,' said Dr. Daniel Radoux, Director Sales & Marketing, Eurogentec About NascaCell Technologies AG – www.nascacell.com NascaCell Technologies AG, based in Munich, is a global leading provider of a new generation of biomolecules. With the innovative Aptamer and Microbody™ technologies, the company supports customers in the target validation and drug discovery R&D areas. NascaCell also develops a line of products and drug development candidates based on the Microbody™ technology. Contact: NascaCell Technologies AG Dr. Michael Blind Chief Scientific Officer Phone: +49 (0)89-54 72 72-0 m.blind@nascacell.de InvestorPress GmbH Georg Breu Phone: +49(0)89 55 96 98 75 info@investorpress.de About Eurogentec – www.eurogentec.com Eurogentec was founded in 1985 as a spin-off of the University of Liège (Belgium). Its mission is to design and deliver reliable and innovative services and products for the Life-Science community. As a leading supplier for genomic and proteomic research, Eurogentec is able to offer its customers integrated solutions, whether they use DNA, antibodies, peptides or proteins as research tools. Eurogentec also offers research and development services for the biopharmaceutical industry. During the past years, Eurogentec has developed a broad platform of enabling technologies. The activities are organised around 2 business units. The 'Tools for Genomics and Proteomics' department offers oligonucleotide synthesis with a large range of modifications, oligonucleotides for In Vitro Diagnostic (IVD), Real-Time PCR products, DNA MicroArray services and a wide range of kits and consumables. It also gathers know-how in the design of peptides, either for antibody production or bioactive peptide purposes. Antibody production in a wide range of animal models as well as Peptide-, Antibody- and ProteinArrays are also amongst its expertise. Eurogentec's 'Biologics' unit is a full-service Contract Manufacturing Organisation (CMO) delivering research, development and production services for cGMP clinical batch manufacturing. The EGT Group currently employs around 280 people, including around 30 PhDs. In 2001, Eurogentec has been awarded 'Belgium's entrepreneur of the Year'. In 2002, Eurogentec received the Walloon Region award for exports in Europe. Contact information Jean-Pierre Delwart, CEO • j.p.delwart@eurogentec.com Daniel Radoux, Director Sales & Marketing d.radoux@eurogentec.com Isabelle Body, Communication Manager • i.body@eurogentec.com EUROGENTEC S.A. LIEGE Science Park B-4102 Seraing - Begium Tel.: +32 4 372 74 00 Fax: +32 4 372 75 00 info@eurogentec.com www.eurogentec.com DGAP 31.07.2007 ----------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden